Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

导出原文传递

翻译打印收藏纠错

作者： Masuda, Kazuhiko ^[1] ; Ono, Atsushi ^[2] ; Aikata, Hiroshi ; Kawaoka, Tomokazu ; Hayes, C. Nelson ; Teraoka, Yuji ; Daijo, Kana ; Nakamura-Inagaki, Yuki ; Morio, Kei ; Fujino, Hatsue ; Kan, Hiromi ; Uchida, Takuro ; Masaki, Keiichi ; Kobayashi, Tomoki ; Nakahara, Takashi ; Makokha, Grace Naswa ; Zhang, Yizhou ; Nagaoki, Yuko ; Miki, Daiki ; Tsuge, Masataka ; Hiramatsu, Akira ; Imamura, Michio ; Abe-Chayama, Hiromi ; Kawakami, Yoshiiku ; Ochi, Hidenori ; Chayama, Kazuaki

作者单位： Hiroshima Univ, Liver Res Project Ctr, Hiroshima, Japan ^[1] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab, Appl Life Sci,Minami Ku, 1-2-3 ^[2]

关键词 Biomarker Liver cancer HCC High mobility group box 1 Sorafenib Hepatic arterial infusion chemotherapy

发布时间 2018-12-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交